These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615 [TBL] [Abstract][Full Text] [Related]
26. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients. Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788 [TBL] [Abstract][Full Text] [Related]
27. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M J Clin Oncol; 2007 Jun; 25(17):2434-41. PubMed ID: 17485707 [TBL] [Abstract][Full Text] [Related]
28. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
29. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803 [TBL] [Abstract][Full Text] [Related]
30. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. Modak S; Gardner S; Dunkel IJ; Balmaceda C; Rosenblum MK; Miller DC; Halpern S; Finlay JL J Clin Oncol; 2004 May; 22(10):1934-43. PubMed ID: 15143087 [TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Alexanian R; Weber D; Delasalle K; Handy B; Champlin R; Giralt S Bone Marrow Transplant; 2004 Aug; 34(3):229-34. PubMed ID: 15170166 [TBL] [Abstract][Full Text] [Related]
33. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574 [TBL] [Abstract][Full Text] [Related]
34. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357 [TBL] [Abstract][Full Text] [Related]
35. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547 [TBL] [Abstract][Full Text] [Related]
36. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704 [TBL] [Abstract][Full Text] [Related]
37. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200 [TBL] [Abstract][Full Text] [Related]
38. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290 [TBL] [Abstract][Full Text] [Related]
39. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
40. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]